New White Paper Calls for Precision Approach to Section 232 in Medical Device Sector


Action for Health Logo

Antonio Ortiz-Mena and Christopher G. Sheeron point out that these tariffs, if implemented improperly, would pose a threat to U.S. hospitals and patients. They also note that, since Medicare reimburses hospitals only 83 cents for every dollar spent, the imposition of broad-ranging or abruptly implemented tariffs could lead to cost-shifting onto patients, increasing their expenses before domestically produced alternatives are fully available to meet demand.


Critical Care: Protecting U.S. Medical Device Leadership Through Targeted Section 232 Action


Antonio Ortiz-Mena and Christopher G. Sheeron emphasize that Section 232 tariffs, if improperly applied, would pose a threat to U.S. hospitals and patients. They also note that, since Medicare reimburses hospitals only 83 cents for every dollar spent, the imposition of broad-ranging or abruptly implemented tariffs could lead to cost-shifting onto patients, increasing their expenses before domestically produced alternatives are fully available to meet demand.


Protecting U.S. Medical Device Leadership Through Targeted Section 232 Action


The United States is at a pivotal moment in medical device trade policy. The authors argue that Medical devices warrant a differentiated rather than uniform Section 232 response. Also, the affordability consequences of Section 232 tariffs in this sector are real, proximate, and asymmetrically distributed. Finally, that origin differentiation is essential to a legally durable and strategically coherent Section 232 framework.